US Pharma MarketingTravere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases
Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, paying $112.5 million upfront for a drug that has already begun the trek into the clinic. Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, handing over $112.5 million upfront for a drug that has already begun the trek into the clinic. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce…
Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, handing over $112.5 million upfront for a drug that has already begun the trek into the clinic.
Source: FierceBiotech